Athira Pharma (Athira Pharma) ROCE % : -85.27% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Athira Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Athira Pharma's annualized ROCE % for the quarter that ended in Dec. 2023 was -85.27%.

Athira Pharma ROCE % Historical Data

The historical data trend for Athira Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athira Pharma ROCE % Chart

Athira Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-182.49

-14.19

-18.46

-31.77

-68.96

Athira Pharma Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-34.68	-52.72	-63.44	-81.86	-85.27

Athira Pharma ROCE % Calculation

Athira Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-126.937	/	( ( (258.153 - 21.431)	+	(160.245 - 28.84) )	/ 2 )
	=	-126.937	/	( (236.722	+	131.405)	/ 2 )
	=	-126.937	/	184.0635
	=	-68.96 %

Athira Pharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-122.568	/	( ( (184.7 - 28.622)	+	(160.245 - 28.84) )	/ 2 )
	=	-122.568	/	( ( 156.078	+	131.405 )	/ 2 )
	=	-122.568	/	143.7415
	=	-85.27 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Athira Pharma (NAS:ATHA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Athira Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Athira Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Athira Pharma (Athira Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athira Pharma Inc (NAS:ATHA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011

Website

https://www.athira.com

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Executives

Mark James Litton	officer: Chief Operating Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Mark Worthington	officer: General Counsel	C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Rachel Lenington	officer: Chief Technology Officer	C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrew Gengos	officer: See Below	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Grant Pickering	director	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
James A Johnson	director	C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Kevin Church	officer: Vice President of Discovery	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Glenna Mileson	officer: Chief Financial Officer	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Kelly A Romano	director	C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915
Hans Moebius	officer: Chief Medical Officer	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Michael A. Panzara	director	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Barbara Kosacz	director	3175 HANOVER STREET, PALO ALTO CA 94304
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014